/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

T

T-E. Ciuleanu

Institute of Oncology Prof. Dr. Ion Chiricuta(RO)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

73

Papers

515

Citations

13

h-index

15

i10-index

T-E. Ciuleanu is an academic researcher from Institute of Oncology Prof. Dr. Ion Chiricuta. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 13, co-authored 63 publications.

Research Topics

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies Colorectal Cancer Treatments and Studies Lung Cancer Diagnosis and Treatment

Papers by this author

works

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

2023 · ESMO Open · 41 citations

https://doi.org/10.1016/j.esmoop.2023.102065

Hossein Borghaei Kenneth J. O’Byrne Luis Paz‐Ares T-E. Ciuleanu

65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

2024 · Immuno-Oncology Technology · 14 citations

https://doi.org/10.1016/j.iotech.2024.100808

Solange Peters Daniel S.W. Tan David E. Gerber James J. Urbanic

OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

2023 · Journal of Thoracic Oncology · 9 citations

https://doi.org/10.1016/j.jtho.2023.09.076

S.S. Ramalingam T-E. Ciuleanu R. Bernabe Makoto Nishio

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’

2021 · ESMO Open · 6 citations

https://doi.org/10.1016/j.esmoop.2021.100345

Martin Reck T-E. Ciuleanu Manuel Cobo Michael Schenker

P3.18.37 A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC With PD-L1 TPS =50%

2025 · Journal of Thoracic Oncology · 0 citations

https://doi.org/10.1016/j.jtho.2025.09.1052

T-E. Ciuleanu R.A. Ramırez Fallas Tuncay Göksel S.J. Kim

OA02.03 Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study

2025 · Journal of Thoracic Oncology · 0 citations

https://doi.org/10.1016/j.jtho.2025.09.033

T. Mitsudomi P.M. Forde N. Girard M. Provencio

Research topics

topics

Lung Cancer Treatments and Mutations

Cancer Immunotherapy and Biomarkers

Lung Cancer Research Studies

Colorectal Cancer Treatments and Studies

Lung Cancer Diagnosis and Treatment

Chat about Author

Papers

Chat

Click to start Chat